[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ahn-Gook Pharmaceuticals Co.,Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":115},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,70,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100608191","phase-3-efficacy-and-safety-of-ag2001-in-patients-with-acute-bronchitis-100608191",false,"NCT07198347","Efficacy and Safety of AG2001 in Patients With Acute Bronchitis","A Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2001 in Patients With Acute Bronchitis","AG2001 P3","Inclusion Criteria:\n\n1. Adults aged ≥19 years to \\\u003C65 years old\n2. Subjects who present symptoms of Acute Bronchitis with cough and sputum symptoms within 48 hours prior the randomization visit(Visit 2) who satisfy the following\n\n   * Total Bronchitis Severity Scale ≥ 5\n   * Total Bronchitis Severity Scale sputum score ≥ 2\n3. Subjects who without fever(condensed body temperature standard: less than 38.5°C) prior to randomization visit(Visit 2)\n4. Subjects who present symptoms of Acute Bronchitis with cough less then 2 weeks prior to randomization visit(Visit 2)\n5. Written consent voluntarily to participate who can understand the information provided in this clinical trial\n\nExclusion Criteria:\n\n* Chronic respiratory diseases (e.g., COPD, asthma, pneumonia, tuberculosis, lung cancer)\n* Clinically significant hepatic, renal, cardiovascular, or neurological disorders\n* Use of prohibited medications (e.g., antibiotics, antivirals, corticosteroids) within the washout period\n* Positive test for hepatitis B, hepatitis C, or HIV\n* Pregnant or breastfeeding women\n* Any condition deemed inappropriate by the investigator","ALL","19 Years","64 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.",[28],"Acute Bronchitis",[30,31,32],"acute bronchitis","Cough","Sputum","NOT_YET_RECRUITING","2025-09-21",{"date":36,"type":37},"2025-09-30","ACTUAL",{"date":39,"type":22},"2025-11-01",{"date":41,"type":22},"2026-10-31",{"name":43,"class":44},"Ahn-Gook Pharmaceuticals Co.,Ltd","INDUSTRY",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100599339","a-study-to-evaluate-the-effectiveness-and-safety-of-fixed-dose-combination-of-pitavastatin-ezetimibe-100599339","NCT07083206","A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin\u002F Ezetimibe","A Multi-center, Prospective, Non-intervention, Observational Study to Evaluate the Effectiveness and Safety of Switching to Pevarozet Tablet in Patients With Hypercholesterolemia Previously Treated With Atorvastatin or Rosuvastatin Monotherapy","PIVOTAL","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Patients diagnosed with hypercholesterolemia who have been stably treated with atorvastatin or rosuvastatin monotherapy for at least 3 months, and for whom switching to fixed-dose combination pitavastatin\u002Fezetimibe has been clinically decided\n* Patients with available clinical laboratory test results related to efficacy and safety (TC, TG, HDL-C, LDL-C, AST, ALT, Cr\u002FeGFR) within 12 months prior to switching to fixed-dose combination pitavastatin\u002Fezetimibe (no changes in statin regimen or dosage during that period)\n* Individuals (or their legally authorized representatives) who voluntarily provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known hypersensitivity or history of hypersensitivity to any component of the investigational product\n* Patients with active liver disease or persistent, unexplained elevations of aminotransferase levels\n* Patients with severe hepatic impairment, biliary obstruction, or cholestasis\n* Patients currently receiving cyclosporine treatment\n* Patients diagnosed with myopathy\n* Pregnant or breastfeeding women, or women who may be pregnant\n* Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption\n* Any patient who, in the opinion of the investigator, is deemed unsuitable for study participation",{"count":54,"type":22},4500,"OBSERVATIONAL","The objective of this study is to evaluate the effectiveness and safety of Pitavastatin\u002FEzetimibe FDC in patients with hypercholesterolemia.",[58,59],"Hypercholesterolemia","Dyslipidemias","RECRUITING","2025-08-03",{"date":63,"type":37},"2025-08-07",{"date":65,"type":37},"2025-07-29",{"date":67,"type":22},"2029-01",{"name":43,"class":44},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100586499","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ag2304-compared-to-coadministration-of-ag23041-and-ag23042-100586499","NCT06916169","A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042","An Open-label, Randomized, Fasting, Single, Group 2, Stage 2, Cross-over Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* A healthy adults aged 19-65 years at the time of screening\n* Subjects who are deemed eligible based on the screening tests\n\nExclusion Criteria:\n\n* Subjects who have taken the investigational drug within 6 months prior to the first dose\n* Other exclusions have been applied",true,"65 Years",{"count":80,"type":22},70,[82],"PHASE1","The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.",[85],"Pharmacokinetics","2025-04-02",{"date":88,"type":37},"2025-04-08",{"date":90,"type":22},"2025-08",{"date":92,"type":22},"2025-09",{"name":43,"class":44},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":77,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100558314","phase-1-bioequivalence-study-of-ag2202-100558314","NCT06549504","Bioequivalence Study of AG2202","An Open-label, Randomized, Fasting, Single, Oral Administration, Group 2, Stage 2, Cross-over Bioequivalence Study of AG2202 in Healthy Volunteers","Inclusion Criteria:\n\n* Subjects aged 19 years or older at the time of screening\n* Subjects with a BMI of 18.0-30.0 kg\u002Fm2\n* Subjects who do not have clinically significant congenital or chronic diseases and who do not have any pathological symptoms or findings as a result of general clinical examination\n* Subjects who are deemed eligible based on the screening tests\n\nExclusion Criteria:\n\n* Subjects who have taken drugs that induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose or who have taken drugs that may interfere with the investigational product within 10 days prior to the first dose\n* Subjects who have taken the investigational drug within 6 months prior to the first dose\n* Subjects who donated whole blood within 8 weeks prior to the first dose, or donated blood components within 2 weeks, or received a blood transfusion within 4 weeks prior to the first dose",{"count":102,"type":22},34,[82],"The objective of this study is to evaluate the human bioequivalence of AG2202T and AG2202R.",[106],"Bioequivalence Study","2024-08-12",{"date":109,"type":37},"2024-08-14",{"date":111,"type":22},"2024-08",{"date":113,"type":22},"2024-09",{"name":43,"class":44},""]